A Proof of Concept and Dose Ranging Study in Patients With Rheumatoid Arthritis

Summary

This study is being carried out to investigate if AZD5672 is effective in treating Rheumatoid Arthritis (RA) and if so how it compares to placebo (a substance which does not have any action) and etanercept (a medicine already available to treat Rheumatoid Arthritis) when added to treatment with methotrexate. The purpose of this study is also to find out which dose of AZD5672 is the most effective at treating RA and to find out how well the body tolerates AZD5672 when taken for up to 12 weeks.

Timeline

Start

2008-07

Primary completion

2009-04

Completion

2009-04

Outcome

Missed primary endpoint

paper There was no statistically significant difference in the proportion of patients achieving an ACR20 response at week 12 between those receiving PMID 20662070 ↗

Publications

• Gerlag DM, Hollis S, Layton M, Vencovsky J, Szekanecz Z, Braddock M, Tak PP; ESCAPE Study Group. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010 Nov;62(11):3154-60. doi: 10.1002/art.27652.

Drugs

Indications